Fortress Biotech shareholders approve issuance of rights and Contingent Subsidiary Securities

Fortress Biotech, Inc.

Special meeting held April 10, 2023; quorum of 60,355,029 shares (53.2%).
Proposal to satisfy Nasdaq Listing Rule 5635(c) approved: 50,498,193 for, 9,743,984 against, 112,852 abstentions.
No broker non-votes on the issuance proposal.
Approval allows issuance of rights and contingent securities in connection with prior financing arrangements.
Vote was required under Nasdaq rules due to potential dilution exceeding 20% of common stock.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Fortress Biotech, Inc. shareholders approved Approval of the issuance of the rights and Contingent Subsidiary Securities in order to satisfy the requirements of Nasdaq Listing Rule 5635(c) at the 2023-04-10 meeting.

Outcome: passed
Meeting: 2023-04-10

Exact text from the filing

Total Votes For Total Votes Against Abstentions Broker Non-Votes 50,498,193 9,743,984 112,852 0

View on SEC.gov

63 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Fortress Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-045012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.